ORIGINAL INVESTIGATION

Metabolic syndrome and myocardium steatosis in subclinical type 2 diabetes mellitus: a $^1$H-magnetic resonance spectroscopy study

Yue Gao$^{1,2}$†, Yan Ren$^3$†, Ying-kun Guo$^2$†, Xi Liu$^1$, Lin-jun Xie$^3$, Li Jiang$^1$, Meng-ting Shen$^1$, Ming-yan Deng$^3$ and Zhi-gang Yang$^1$*

Abstract

Background: Metabolic syndrome (MetS) is a cluster of metabolic abnormalities that collectively cause an increased risk of type 2 diabetes mellitus (T2DM) and nonatherosclerotic cardiovascular disease. This study aimed to evaluate the role of myocardial steatosis in T2DM patients with or without MetS, as well as the relationship between subclinical left ventricular (LV) myocardial dysfunction and myocardial steatosis.

Methods and materials: We recruited 53 T2DM patients and 20 healthy controls underwent cardiac magnetic resonance examination. All T2DM patients were subdivide into two group: MetS group and non-MetS. LV deformation, perfusion parameters and myocardial triglyceride (TG) content were measured and compared among these three groups. Pearson's and Spearman analysis were performed to investigate the correlation between LV cardiac parameters and myocardial steatosis. The receiver operating characteristic curve (ROC) was performed to illustrate the relationship between myocardial steatosis and LV subclinical myocardial dysfunction.

Results: An increase in myocardial TG content was found in the MetS group compared with that in the other groups (MetS vs. non-MetS: 1.54 ± 0.63% vs. 1.16 ± 0.45%; MetS vs. normal: 1.54 ± 0.63% vs. 0.61 ± 0.22%; all p < 0.001). Furthermore, reduced LV deformation [reduced longitudinal and radial peak strain (PS); all p < 0.017] and microvascular dysfunction [increased time to maximum signal intensity (TTM) and reduced Upslope; all p < 0.017] was found in the MetS group. Myocardial TG content was positively associated with MetS ($r = 0.314$, $p < 0.001$), and it was independently associated with TTM ($\beta = 0.441$, $p < 0.001$) and LV longitudinal PS ($\beta = 0.323$, $p = 0.021$). ROC analysis exhibited that myocardial TG content might predict the risk of decreased LV longitudinal myocardial deformation (AUC = 0.74) and perfusion function (AUC = 0.71).

Conclusion: Myocardial TG content increased in T2DM patients with concurrent MetS. Myocardial steatosis was positively associated with decreased myocardial deformation and perfusion dysfunction, which may be an indicator for predicting diabetic cardiomyopathy.

Keywords: Myocardial steatosis, Metabolic syndrome, Subclinical myocardial dysfunction, $^1$H-magnetic resonance spectroscopy

Introduction

Current literature outlines that the excessive accumulation of lipid in cardiomyocytes (myocardial steatosis) is bound to facilitate myocardial lipotoxic injury, which, plays an important role in the development of diabetic...
cardiomyopathy [1–3]. On the other hand, metabolic syndrome (MetS) is a cluster of risk factors such as central obesity, hyperglycemia, dyslipidemia and hypertension that collectively increase the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease [4]. Central obesity is one of the most evident clinical features of MetS. Therefore, its development has a prominent role in MetS diagnosis [5]. Chronic inflammation caused by central obesity has been described as an essential factor in the occurrence and development of MetS, and the transition of MetS to cardiovascular disease [6]. Moreover, ectopic fat accumulates around the viscera and regularly enters tissues with only minor amount of adipose tissue such as the heart [7]. At present, there are few studies investigating the myocardial steatosis in T2DM patients with concurrent MetS, and its influence on subclinical cardiac dysfunction.

In recent decades, cardiac magnetic resonance (CMR) imaging has been commonly used in clinical practice, which can provide various characteristics of cardiac structure and myocardial tissue [8–13]. More specifically, feature tracking and first-pass perfusion of CMR imaging have been used to measure myocardial deformation and to detect microvascular dysfunction. On the other hand, proton Magnetic Resonance Spectroscopy (1H-MRS) can quantitatively detect triglyceride (TG) content in the myocardium. Therefore, this study aimed to evaluate myocardial steatosis using CMR in T2DM patients with or without concurrent MetS and to investigate the association between left ventricular (LV) subclinical myocardial dysfunction and myocardial steatosis.

Methods and materials

Study population

Initially, we prospectively enrolled 92 patients, who were diagnosed with T2DM according to the World Health Organization standards, between June 2017 and May 2019 [14]. Exclusion criteria were as follow: [1] contraindication of CMR; [2] known cardiovascular disease or congenital heart disease; [3] presence of dyspnea, chest pain, palpitation or other cardiovascular disease-related symptoms; and [4] impaired hepatic function or a history of liver disease. Following these criteria, a total of 53 T2DM patients (31 males and 22 females; mean age 54.49 ± 11.16 years) were finally included in this study. In addition, age-, sex-, and body mass index-matched healthy volunteers were recruited in the controls group. Exclusion criteria for the control group were as follows: [1] DM or impaired glucose tolerance; [2] known acute or chronic disease such as hypertension; [3] disease-hyperlipidemia; [4] electrocardiogram abnormalities; and [5] cardiovascular abnormalities detected by CMR (perfusion defect, local, or diffuse myocardial late-gadolinium enhancement, abnormal ventricular motion, valvular stenosis, etc.). Hence, 20 healthy controls (11 males and 9 females; mean age 50.95 ± 10.185 years) were included in this study. Consequently, all T2DM patients and controls underwent CMR provided that they have provided their informed written consent. The study protocol was approved by the West-China hospital of Sichuan University Biomedical Research Ethics Committee.

Clinical characteristics, medication, and serum biochemical indexes of all patients and healthy controls were collected. Blood pressure was measured approximately 20 min before CMR examinations when the subject was in a relaxed state. Blood sampling for serum biochemical indexes was performed within 1 week of the CMR scan without changing the subject’s medication regimen.

Adhering to the definition of MetS by the International Diabetes Federation (2005), we divided T2DM patients into MetS and non-MetS groups [15]. In this definition, central obesity is considered an essential diagnostic element for MetS, and be defined as waist circumference of ≥ 90 cm for males and ≥ 80 cm for females. In addition, the presence of any two of these factors is sufficient for the diagnosis of MetS: (a) increased plasma TG levels (> 150 mg/dL [1.7 mmol/L]) or specific treatment for this lipid abnormality; (b) reduced high-density lipo-protein (HDL)-cholesterol (< 40 mg/dL [1.0 mmol/L] in males; < 50 mg/dL [1.3 mmol/L] in females) or specific treatment for this lipid abnormality; (c) increased blood pressure (systolic ≥ 130 mm Hg and/or diastolic ≥ 85 mm Hg) or treatment of previously diagnosed hypertension; and (d) increased fasting plasma glucose levels (> 100 mg/dL [5.6 mmol/L]) or previously diagnosed T2DM.

CMR scanning protocol

All subjects were examined using a 3.0-T whole-body scanner (Skrya; Siemens Medical Solutions, Erlangen, Germany) in the supine position. A dedicated two-element cardiac-phased array coil was used for signal detection. Furthermore, a standard ECG-triggering device was used and end-inspiratory breath holding were performed. Following a survey scan, cine images such as long-axis four-chamber views and short-axis two-chamber views were acquired using a steady-state free-precession sequence (TR/TE 39.34/1.22 ms, flip angle 38°, slice thickness 8 mm, field of view 360 × 300 mm², matrix size 256 × 166). Regarding first-pass perfusion imaging, gadobenate dimeglumine (MultiHance; Bracco, Milan, Italy) was intravenously injected at a dose of 0.2 ml/kg body weight at an injection rate of 2.5–3.0 mL/s, followed by a 20 ml saline flush at a rate of 3.0 ml/s. Consequently, first-pass perfusion images were acquired using an inversion-recovery echo-planar imaging sequence (TR/TE 163.00/0.98 ms, flip angle 10°, slice thickness 8 mm, field
of view $360 \times 270$ mm$^2$, matrix size $256 \times 192$) with three standard short-axis slices (apical, middle, and basal), as well as basal slices do not cover the mitral valve level.

$^1$H-MRS were performed to obtain the myocardial TG content using a standard flex-coil for signal reception. Voxel positioning was performed in the standard 4-chamber view and 2-chamber short-view, and a single voxel was positioned on the interventricular septum in the middle slice (Fig. 1). Spectroscopic data were acquired with ECG triggering and respiratory navigator echoes to minimize motion artifacts. We performed two scans using the abovementioned sequence. During the first scan, the water suppression mode was used to eliminate the imbibition caused by water from the signal of interest. During the second scan, the water suppression mode was not used, a water signal is obtained. Spectral data collection was performed with the PRESS sequence (TR/TE 560/33 ms, average 4). All 1H-MRS data were analyzed using a Java-based software (jMRUI, version 6.0, Leuven, Belgium). TG content was calculated as a percentage related to water and expressed as following:

$$\frac{\text{signal amplitude of TG}}{\text{signal amplitude of water}} \times 100$$

**CMR data analysis**

We uploaded all acquired images data to an offline workstation using a semi-automated software (Cvi42; Circle Cardiovascular Imaging, Inc., Calgary, Canada). Endocardial and epicardial traces were delineated manually by two experienced radiologists in the serial short-axis slices during the end-diastolic and end-systolic phases. LV functional parameters and LV mass were automatically determined. LV remodeling was characterized by the ratio of LV mass to LVEDV (LVMVR). The LV global function index (LVGFI) was calculated using the following formula:

$$\frac{\text{signal amplitude of TG}}{\text{signal amplitude of water}} \times 100$$
LVGFI = \{\frac{LVSV}{(LVEDV + LVESV)/2} + (LV mass/1.05)}\times100

To evaluate LV microvascular perfusion, blood pools as well as endocardial and epicardial traces of the middle slice of first-pass perfusion images were delineated manually (in order to match the voxel level of H-MRS), and a region of interest was placed over the blood pool as a means of contrast. In addition to myocardial and blood pooled time-signal intensity curves, semi-quantitative perfusion parameters were obtained such as upslope, maximum signal intensity (MaxSI), and time to maximum signal intensity (TTM).

Variability analysis
To determine intra-observer variability, LV deformation and perfusion parameters in 30 random cases that included 20 T2DM patients and 10 normal controls were measured twice in 1-week intervals by a radiologist. Then, a second investigator, who was blinded to the first investigator’s results, reanalyzed the measurements. Finally, the interobserver variability was assessed on the basis of the two investigators’ results. The two radiologists were blinded to the status (DM vs control, DM with MetS vs. DM without MetS).

Statistical analysis
Statistical analyses were performed with commercially available SPSS (version 21.0 for windows; SPSS, Inc., Chicago, IL, USA). Results are expressed as the mean ± standard deviation. One-way analysis of variance test was performed to evaluate the differences among the following groups: T2DM with MetS, T2DM without MetS and control. Based on Bonferroni’s correction for the following groups: T2DM with MetS, T2DM without MetS and control, a p-values of<0.017 were considered as statistically significant. Spearman’s and Pearson’s correlation analysis were conducted to identify the relationship between myocardial steatosis and cardiac dysfunction. Moreover, multivariable stepwise linear regression analysis was employed to identify the relationship between myocardial TG content and subclinical cardiac dysfunction. Receiver operating characteristic curve (ROC) analysis was conducted to predict myocardial steatosis to LV subclinical myocardial dysfunction.

Results
Patient characteristics and metabolic parameters
Of the 53 T2DM patients, 23 were included in the non-MetS (15 males, mean age 54.85 ± 10.87 years) and 30 in the MetS group (16 males, mean age 54.48 ± 9.61 years). Table 1 presents their baseline characteristics, metabolic parameters, and medication. Weight and BMI were found to be higher in the MetS group than in the non-MetS group and the control group, whereas systolic blood pressure was higher in the MetS group than in the control group.

HbA1c was higher in T2DM patients than in normal controls, and serum TG content was higher in the MetS group than in the control group (1.76 ± 1.64 mmol/L vs. 1.03 ± 0.27 mmol/L; p < 0.001). In terms of medication, the MetS group were more likely to received treatment for this lipid abnormality. The remaining baseline and metabolic characteristics showed no statistically significant difference among all the three groups.

CMR H-MRS analysis
The result of the myocardial TG content are summarized in Table 2. The MetS group had significantly higher myocardial TG content than that of the non-MetS group (1.54 ± 0.63% vs. 1.16 ± 0.45%, p < 0.001) and the control (1.54 ± 0.63% vs. 0.61 ± 0.22%, p < 0.001; Fig. 2a). Furthermore, the non-MetS group had a significantly higher myocardial TG content than the control group (1.16 ± 0.45% vs. 0.61 ± 0.22%, p < 0.001).

CMR imaging analysis
Regarding LV function and deformation, LVEDV, LVESV and LVGFI (all p < 0.001) were lower in the MetS group compared to the control group, whereas LV mass (92.25 ± 22.81 g/m² vs. 75.93 ± 14.33 g/m² p < 0.001) and LVMVR (0.76 ± 0.22 vs. 0.55 ± 0.13, p < 0.001) were higher in the MetS group than in the control group.

The global longitudinal peak strain (PS) (MetS vs. non-MetS: −12.67 ± 3.46% vs. −14.78 ± 3.48%; MetS vs. control: −12.67 ± 3.46% vs. −15.71 ± 2.10%, all p < 0.001) (Fig. 2b) and global radial PS (MetS vs. non-MetS: 33.28 ± 9.00% vs. 39.98 ± 12.05%; MetS vs. normal: 33.28 ± 9.00% vs. 39.85 ± 7.64%, all p < 0.001) (Fig. 2c) were lower in the MetS group than in the non-MetS and control groups. There was no statistically significant difference in myocardial deformation between the non-MetS and control group.

T2DM patients in MetS group had a significantly lower perfusion upslope (2.10 ± 1.19 vs. 2.93 ± 0.78, p < 0.001) (Fig. 2d) but higher TTM values (36.09 ± 14.57 s vs. 24.77 ± 11.01 s, p < 0.001) (Fig. 2e) than the control group. However, no difference was observed in these values compared with the non-MetS group. In fact, there was no significant difference in terms of all perfusion parameters between the non-MetS and the control group.
Association between MetS, myocardial steatosis, and myocardial function

Spearman correlation analysis showed that MetS had a positive correlation with myocardial TG content ($r = 0.314$, $p < 0.05$). Furthermore, myocardial TG content was positively associated with LV longitudinal PS ($r = 0.359$, $p < 0.05$), TTM ($r = 0.415$, $p < 0.05$), and negatively associated with upslope ($r = -0.280$, $p < 0.05$) (Fig. 3). There was no significant correlation between MetS and other cardiac-related parameters (all $p > 0.05$).

Multivariable stepwise linear regression analysis indicated that myocardial TG content ($\beta = 0.441$, $p < 0.001$) and diastolic blood pressure ($\beta = 0.254$, $p = 0.041$) were independently associated with the TTM (Model 3: $R^2 = 0.459$), and the myocardial TG content ($\beta = 0.323$, $p = 0.021$) was also independently associated with LV longitudinal PS (Model 3: $R^2 = 0.323$) (Table 3).

ROC analysis demonstrated that the cutoff value for myocardial TG content that predicted the risk of myocardial microvascular perfusion dysfunction (sensitivity = 57.1%, specificity = 84.0%, and AUC = 0.74) (Fig. 4a) and longitudinal myocardial deformation (sensitivity = 59.2%, specificity = 84.6%, and AUC = 0.71) (Fig. 4b) was 1.56.

Inter- and intra-observer variability

Table 4 summarizes the inter- and intra-observer variability for LV deformation and first-pass perfusion analysis. The ICCs for intra- and interobserver variability were 0.923–0.959 and 0.883–0.955, respectively, in LV

---

**Table 1 Baseline and metabolic parameters T2DM patients with or without metabolic syndrome and the normal controls**

|                          | Normal (n = 20) | Non-MetS (n = 23) | MetS (n = 30) |
|--------------------------|----------------|-------------------|---------------|
| **Baseline characteristics** |                |                   |               |
| Age (y)                  | 50.95 ± 10.185 | 54.85 ± 10.87     | 54.48 ± 9.61  |
| Male (n)                 | 10 (50.0%)    | 15 (65.2%)        | 16 (53.3%)    |
| High (cm)                | 162.70 ± 7.08 | 162.85 ± 9.23     | 164.13 ± 7.29 |
| Weigh (kg)               | 61.30 ± 5.96  | 58.52 ± 8.22      | 66.54 ± 8.55*β|
| BMI                      | 23.14 ± 1.49  | 22.03 ± 2.30      | 24.71 ± 3.05β|
| Systolic blood pressure (mmHg) | 119.45 ± 7.22 | 130.36 ± 16.86    | 132 ± 19.22*β|
| Diastolic blood pressure (mmHg) | 78.75 ± 7.81  | 76.42 ± 7.67      | 80.09 ± 10.53 |
| Duration of diabetes (y) | –              | 7.32 ± 7.24       | 7.90 ± 4.59   |
| Waist circumference (cm) | –              | 83.33 ± 5.79      | 93.37 ± 1.05  |
| **Metabolic characteristics** |                |                   |               |
| HbA1c (%)                | 5.38 ± 0.34   | 6.47 ± 2.87*      | 6.75 ± 2.76*  |
| GLU (mmol/l)             | 5.07 ± 0.43   | 7.11 ± 5.12*      | 5.70 ± 3.94   |
| TG (mmol/l)              | 1.03 ± 0.27   | 1.14 ± 0.41       | 1.76 ± 1.64*β |
| TC (mmol/l)              | 4.30 ± 0.57   | 4.29 ± 0.86       | 4.59 ± 0.83   |
| HDL (mmol/l)             | 1.31 ± 0.28   | 1.47 ± 0.34       | 1.23 ± 0.36   |
| LDL (mmol/l)             | 2.71 ± 0.53   | 2.36 ± 0.73       | 2.70 ± 0.74   |
| Creatinine (μmol/l)      | –              | 66.20 ± 12.59     | 73.97 ± 22.15 |
| GFR (30 ml/min)          | –              | 99.84 ± 10.32     | 95.85 ± 19.17 |
| AST (U/l)                | –              | 23.00 ± 12.07     | 25.58 ± 15.82 |
| ALT (U/l)                | –              | 24.53 ± 8.94      | 23.04 ± 8.94  |
| Uric acid (μmol/l)       | 340.00 ± 37.04| 331.81 ± 60.49    | 359.88 ± 95.95|
| Medication, n (%)        |                |                   |               |
| Insulin                  | –              | 7 (33%)           | 10 (31%)      |
| Metformin                | –              | 11 (52%)          | 19 (59%)      |
| Sulfonylurea             | –              | 2 (9%)            | 9 (28%)       |
| α-Glucosidase inhibitor  | –              | 5 (24%)           | 16 (50%)      |
| ACEI                     | –              | 0                 | 4 (13%)       |
| Statin                   | –              | 2 (9%)            | 7 (22%)       |

The values are the mean ± SD. BMI, body mass index; HbA1c, glycated hemoglobin; GLU, glucose; TG, triglycerides; TC, triglyceride; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; GFR, glomerular filtration rate; AST, aspartate transaminase; ALT, alanine transaminase.

*P < 0.017 versus normal group
βP < 0.017 versus T2DM in non-MetS group
deformation and 0.977–0.991 and 0.982–0.993 respectively, in first-pass perfusion, suggesting that both techniques are in agreement.

Discussion

In this study, the following principal findings were obtained: (1) T2DM patients with MetS may be more likely to present myocardial steatosis; (2) there was a decreased of LV deformation and microcirculation perfusion in T2DM patients with MetS; and (3) an increased myocardial TG content was associated with the reduced LV longitudinal deformation and microvascular perfusion, and it might be an appropriate predictor of the myocardium damages.

As a noninvasive technique, 1H-MRS MRS can investigate the cardiac metabolism in vivo, thereby quantitatively detecting metabolites, including fatty acids (FA), creatine etc. Therefore, 1H-MRS can help diagnose myocardial steatosis at an early stage and facilitate the targeted treatment of diabetes mellitus.

The pathological mechanism of diabetic cardiomyopathy is complex and multifactorial. Recent studies have indicated that myocardial lipotoxic injury as a result of lipid oversupply plays an important role in diabetic heart disease [16, 17]. In this study, we identified the progression of myocardial steatosis (increasing of myocardial TG content) in T2DM patients, particularly in those with concurrent MetS, and it was positively associated with MetS. We suspect that this was due to insulin resistance, central obesity, and increased serum FA content, which leads to increased myocardial FA delivery and uptake in T2DM patients [18]. Furthermore, central obesity was one of the most critical factors that facilitated excessive myocardium lipids deposition in MetS patients [19]. Therefore, T2DM patients with concurrent MetS are more prone to developing myocardial steatosis.

In addition, we observed that only the MetS group exhibited reduced LV longitudinal and radial PS, which might mean reduction of early myocardial diastolic function. According to the distribution of myocardial fibers, the longitudinal myocardial fibers are predominantly located in the sub-endocardium and are most susceptible to early microvascular ischemia [20]. As the central clinical features of MetS, insulin resistance and central obesity increase the inflammation and oxidative stress, thereby inducing endothelial dysfunction and cardiomyocyte apoptosis reducing the ability of myocardial deformation, and ultimately damaging the myocardium; this results in decreased LV deformation of varying degrees [21]. Moreover, our observations related to upslope and TTM indicated that microcirculation function considerably decreased in T2DM patients with MetS. Whereas,

### Table 2 CMR parameters for T2DM patients with or without metabolic syndrome and the normal controls

| 1H-MRS       | Normal (n = 30) | Non‑MetS (n = 23) | MetS (n = 30) |
|--------------|----------------|------------------|--------------|
| Myocardium TG (%) | 0.61 ± 0.22    | 1.16 ± 0.45*    | 1.54 ± 0.63*β |
| Cardiac function |               |                  |              |
| LVEDV (ml/m²) | 75.89 ± 12.94  | 69.92 ± 14.33    | 66.20 ± 12.10* |
| LVESV (ml/m²) | 28.57 ± 6.17   | 25.17 ± 7.24     | 25.98 ± 6.54  |
| LVSV (ml/m²)  | 47.30 ± 8.12   | 44.74 ± 8.95     | 40.22 ± 8.945* |
| LVEF (%)      | 62.47 ± 4.09   | 64.32 ± 6.06     | 60.82 ± 7.62  |
| LV mass (g/m²)| 75.93 ± 14.33  | 82.91 ± 26.11    | 92.25 ± 22.81* |
| LVGFI (%)     | 51.97 ± 6.60   | 47.33 ± 6.75     | 46.02 ± 9.43* |
| LVMVR         | 0.55 ± 0.13    | 0.65 ± 0.15      | 0.76 ± 0.22*  |
| LV stain      |                |                  |              |
| Radial PS (%) | 39.85 ± 7.64   | 39.98 ± 12.05    | 33.28 ± 9.00*β |
| Circumferential PS (%) | −20.41 ± 2.50 | −19.34 ± 3.48    | −19.38 ± 2.32 |
| Longitudinal PS (%) | −15.71 ± 2.10 | −14.78 ± 3.48    | −12.67 ± 3.46*β |
| First perfusion |               |                  |              |
| Upslope      | 2.93 ± 0.78    | 2.45 ± 1.20      | 2.10 ± 1.19* |
| MaxSI        | 24.19 ± 6.14   | 23.46 ± 9.13     | 20.65 ± 7.94  |
| TTM (s)      | 24.77 ± 11.01  | 30.44 ± 14.71    | 36.09 ± 14.57* |
| MaxSI        | 24.77 ± 11.01  | 30.44 ± 14.71    | 36.09 ± 14.57* |

The values are the mean ± SD. LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, LVSV left ventricular stroke volume, LVEF left ventricular ejection fraction, LVGFI left ventricular global function index, LVMVR LV mass to LV end diastolic volume ratio, PS peak strain, TTM time to maximum signal intensity

*P < 0.017 versus normal group
βP < 0.017 versus T2DM in non-MetS group
despite the reduction trend presented, there was no statistical difference in the non-MetS group and normal control group. It means that when T2DM patients are accompanied by MetS, their myocardial microvascular is reduced, we can presume that compared with subcutaneous fat, central obesity may cause more serious myocardial damage because it is associated with the adverse remodeling of intramural coronary arterioles. Therefore, the impaired vasodilation further reduced myocardial microvascular perfusion8 [22–28].

An additional finding in our study was that the T2DM in MetS group exhibited a tendency of concentric LV remodeling and reduced of LVGFI. In contrast, the T2DM patients in non-MetS group did not present similar myocardial structural changes. Concentric LV remodeling is considered to be an early sign of obesity-related
cardiac remodeling before LV hypertrophy occurs [29]. It has been reported that LV wall thickening is associated with radial strain [30]. Therefore, LV concentric remodeling can lead to myocardial hypertrophy, and radial strain can be reduced to a varying degree. In our study, the LV global radial PS was decreased in the MetS group. In addition, we hypothesize that in addition to insulin resistance and central obesity, other pathological disorders secondary to metabolic ones, such as hypertension, hyperlipidemia, and hyperglycemia, may continue to cause more serious myocardial lesions in T2DM patients with concurrent MetS than in those without MetS [31].

A previous study has identified myocardial steatosis may play an important mechanistic role in the development of diastolic dysfunction in women with microvascular dysfunction and no obstructive CAD [32]. In our study we found the similar mechanism in T2DM patients. Our results show the association between myocardial steatosis and longitudinal PS, this also confirms that T2DM patients are prone to early diastolic dysfunction [8]. Moreover, using electrocardiographically gated gradient-echo sequence with velocity encoding, Rijzewijk et al. found that myocardial steatosis is an independent predictor of early diastolic dysfunction in uncomplicated T2DM [33]. Our present study also reached a similar conclusion using CMR, in that the correlation between myocardial TG content and myocardial deformation decreased in T2DM patients with MetS. Besides myocardial deformation, we also identified that an increase in myocardial TG content is negatively related to myocardial microvascular perfusion function, regardless of patients’ age, BMI, heart rate, duration of diabetes, plasma glucose, and blood pressure, and myocardial TG content had a moderately predictive effect on the myocardial microvascular perfusion. Furthermore, Nyman et al. found that MetS

### Table 3 Multivariable associations between cardiac parameters and myocardial triglyceride content

|                | TTM                  | Longitudinal PS       |
|----------------|----------------------|-----------------------|
|                | Beta | p value | R² | p value | Beta | p value | R² | p value |
| Model 1        |      |         |    |         |      |         |    |         |
| Myocardial TG content | 0.415 | 0.020 | –  | –       | 0.339 |          |    |         |
| Model 2        |      |         |    |         |      |         |    |         |
| Myocardial TG content | 0.415 | <0.001 | 0.413 | <0.001 | 0.308 | 0.025 | 0.308 | 0.025 |
| Duration of diabetes | –     | –       | –  | –       | –     | –       | –  | –       |
| BMI            | –     | –       | –  | –       | –     | –       | –  | –       |
| Model 3        |      |         |    |         |      |         |    |         |
| Myocardial TG content | 0.441 | <0.001 | 0.459 | <0.001 | 0.323 | 0.021 | 0.323 | 0.021 |
| Duration of diabetes | –     | –       | –  | –       | –     | –       | –  | –       |
| BMI            | –     | –       | –  | –       | –     | –       | –  | –       |
| Systolic blood pressure | –     | –       | –  | –       | –     | –       | –  | –       |
| Diastolic blood pressure | 0.254 | 0.041 | –  | –       | –     | –       | –  | –       |
| Age            | –     | –       | –  | –       | –     | –       | –  | –       |
| Glu            | –     | –       | –  | –       | –     | –       | –  | –       |
was associated with LV diastolic dysfunction, and our research indicated that when T2DM is accompanied with MetS, the injury of LV deformation and microvascular perfusion is aggravated ([7]). To order to adapt to metabolic disorder, the myocardium maintains a high oxygen consumption rate and FA oxidation rate under conditions of insulin resistance, visceral adiposity, and increased serum dietary FA content, thus facilitating the accumulation of intracellular TG in the myocyte cytoplasm [34, 35]. Intracellular TG is relatively inert, but an increase in its content reflects a respective increase in anaerobic oxidation of FA and accumulation of lipotoxic intermediates such as ceramide and diacyl-glycerol [18, 36–38]. These lipotoxic intermediates have been shown to activate signaling pathways that affect ATP production, insulin sensitivity, and apoptosis, but they also trigger replacement fibrosis and myocardial contractile dysfunction [18, 39]. Therefore, we believe that T2DM patients with concurrent MetS are more prone to developing myocardial lipotoxic injury, thus suggesting that T2DM and MetS have synergistic effects on myocardial degeneration and myocardial injury.

**Limitations**

There are several limitations to our study. First of all, this study was a single center study; hence, an assemble bias may have influenced the acquired results. Second, because we did not perform secondary CMR examinations or other follow-up investigations, our results need to be verified by longitudinal studies on T2DM patients. Hence, it is our principle focus to verify these findings in future follow-up studies.

**Conclusion**

Our study found that even when the cardiac function of patients with T2DM is preserved, the combined MetS may increase the reduction of myocardial deformation and myocardial perfusion, and these changes in myocardial structure are related to the degree of myocardial steatosis. Meanwhile, myocardial triglyceride content might be a useful indicator to predicting...
diabetic cardiomyopathy. Therefore, it is suggested that we should pay more attention to myocardial steatosis in clinically diabetic patients with metabolic syndrome, and reducing myocardial steatosis may also help prevent the progression of diabetic cardiomyopathy.

Abbreviations
T2DM: Type 2 diabetes mellitus; MetS: Metabolic syndrome; BMI: Body mass index; HDL: High density lipoprotein; TG: Plasma triglycerides; CMR: Cardiovascular magnetic resonance; LV: Left ventricular; EDV: End-diastolic volume; ESV: End-systolic volume; SV: Stroke volume; EF: Ejection fraction; TTM: Time to maximum signal intensity; MaxSI: Max signal intensity; 1H-MRS: Proton Magnetic Resonance Spectroscopy; PS: Peak strain; ROC: The receiver operating characteristic curve.

Acknowledgements
Not applicable.

Authors’ contributions
YG and YR designed the study. YG performed the experiments, and wrote the manuscript. GYK participated in the study design, analyzed the data, drafted the manuscript and editing and review of the manuscript. YZG supervised the overall study and contributed to study design, editing and review of the manuscript. RY, LX performed the experiments and review the manuscript. HBY, LJ, LIX, MTS and DMY performed the experiments and was responsible for collecting, sorting and statistical data. ZOY is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (81771887, 81771897, 81471721, 81471722, 81971586, and 81901712), Program for New Century Excellent Talents in University (No. NCET-13-0386), Program for Young Scholars and Innovative Research Team in Sichuan Province of China (2017TD0005), 1-3-5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD18013).

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study complied with the Declaration of Helsinki and was approved by the West-China hospital of Sichuan University biomedical research ethics committee (Chengdu, Sichuan, China. No. 2016-24). Written informed consents were obtained from all the study participants.

Consent for publication
Not applicable.

Competing interests
The authors declare that there are no conflicts of interest.

Author details
1 Department of Radiology, West China Hospital, Sichuan University, 37# Guo Xue Xiang, Chengdu, Sichuan 610041, China. 2 Department of Radiology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China. 3 Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, 37# Guo Xue Xiang, Chengdu, Sichuan 610041, China.

Received: 22 November 2019 Accepted: 17 May 2020 Published online: 29 May 2020

References
1. Mauger C, Gilbert K, Lee AM, et al. Right ventricular shape and function: cardiovascular magnetic resonance reference morphology and biventricular risk factor morphometrics in UK Biobank. J Cardiovasc Magn Reson. 2019;21(1):41.
2. Yoneyama K, Venkatesh BA, Wu CO, Mewton N, Gjesdal O, Kishi S, McClelland RL, Bluemke DA, Lima JA. Diabetes mellitus and insulin resistance associate with left ventricular shape and torsion by cardiovascular magnetic resonance imaging in asymptomatic individuals from the multi-ethnic study of atherosclerosis. J Cardiovasc Magn Reson. 2019;11(1):652–3.
3. Korosoglou G, Humpert PM, Ahrens J, et al. Left ventricular diastolic function in type 2 diabetes mellitus is associated with myocardial triglyceride content but not with impaired myocardial perfusion reserve. J Magn Reson Imaging. 2012;35(4):804–11.
4. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and Management of the Metabolic Syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2006;112:2735–52.
5. O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16(1):1–12.
6. Yogita R, Pothineni SR. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Vaccines. 2018;8(1):25–32.
7. Nyman K, Granér M, Pentikäinen MO, et al. Cardiac steatosis and left ventricular function in men with metabolic syndrome. J Cardiovasc Magn Reson. 2013;15(1):1–11.
8. Liu Xi, Yang Zhi-gang, Gao Yue, et al. Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study. Cardiovasc Diabetol. 2018;17(1):1–12.
9. Romano S, Judd RM, Kim RJ, et al. Left Ventricular Long-Axis Function Assessed with Cardiac Cine MR Imaging Is an Independent Predictor of All-Cause Mortality in Patients with Reduced Ejection Fraction: a Multi-center Study. Radiology. 2018;286(2):452–60.
10. Karur GR, Robison S, Iwarnochko RM, et al. Use of myocardial T1 mapping at 30 T to differentiate anderson-fabry disease from hypertrophic cardiomyopathy. Radiology. 2018;288(2):398–406.
11. Patscheider H, Lorbeer R, Auweter S, et al. Subclinical changes in MRI-determined right ventricular volumes and function in subjects with prediabetes and diabetes. Eur Radiol. 2018;28(7):3105–13.
12. Dobrovie M, Barreno-Perez M, Cunione D, et al. Inter-vendor reproducibility and accuracy of segmental left ventricular strain measurements using CMR feature tracking. Eur Radiol. 2019;29(12):6846–57.
13. Cao JJ, Ngai N, Duncanson L, et al. A comparison of both DENSE and feature tracking techniques with tagging for the cardiovascular magnetic resonance assessment of myocardial strain. J Cardiovasc Magn Reson. 2018;20(1):26.
14. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.
15. Kgmm A, Pz Z, Shaw J. The metabolic syndrome—a new worldwide definition from the international diabetes federation consensus. Lancet. 2005;366:1059–62.
16. Lewelt E, Pavlidis M, Banerjee R, et al. Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes. J Am Coll Cardiol. 2016;68(1):53–63.
17. Hu L, Zha YF, Wang L, et al. Quantitative evaluation of vertebral microvascular permeability and fat fraction in alloxan-induced diabetic rabbits. Radiology. 2018;287(1):128–36.
18. NgdF AC, Delgado V, Bertini M, et al. Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation. 2010;122:2538–44.
19. Iozzo P. Metabolic toxicity of the heart: insights from molecular imaging. Nutr Metab Cardiovasc Dis. 2010;20(3):147–56.
20. Vinereanu D, Lim PO, Frenneaux MP, et al. Reduced myocardial velocities of left ventricular long-axis contraction identify both systolic and diastolic heart failure—a comparison with brain natriuretic peptide. Eur J Heart Fail. 2005;7(4):512–9.
21. Murai J, Nishizawa H, Otsuka A, et al. Low muscle quality in Japanese type 2 diabetic patients with visceral fat accumulation. Cardiovasc Diabetol. 2018;17(1):112.
22. Hulten EA, Bittencourt MS, Preston R, et al. Obesity, metabolic syndrome and cardiovascular prognosis: from the Partners coronary computed tomography angiography registry. Cardiovasc Diabetol. 2017;16(1):1–11.
23. Mancusi C, de Simone G, Best LG, et al. Myocardial mechano-energetic efficiency and insulin resistance in non-diabetic members of the Strong Heart Study cohort. Cardiovasc Diabetol. 2019;18(1):56.
24. Klein C, Brunereau J, Lacroix D, et al. Left atrial epicardial adipose tissue radiodensity is associated with electrophysiological properties of atrial myocardium in patients with atrial fibrillation. Eur Radiol. 2019;29(6):3027–35.
25. Granér M, Siren R, Nyman K, et al. Cardiac steatosis associates with visceral obesity in non-diabetic obese men. J Clin Endocrinol Metab. 2013;98(3):1189–97.
26. Levy BI, Schiffin EL, Mourad JJ, et al. Impaired tissue perfusion a pathology common to hypertension, obesity, and diabetes mellitus. Circulation. 2008;118(9):968–76.
27. Mandy D, Eschalier R, Kearney-Schwartz A, et al. Comprehensive MRI analysis of early cardiac and vascular remodeling in middle-aged patients with abdominal obesity. J Hypertens. 2012;30(3):567–73.
28. Christensen RH, von Scholten BJ, Hansen CS, et al. Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes. Cardiovasc Diabetol. 2019;18(1):1–10.
29. Wolf P, Winhofer Y, Krssak M, et al. Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes. Nutr Metab Cardiovasc Dis. 2016;26(5):387–92.
30. Chitiboi T, Axel L. Magnetic resonance imaging of myocardial strain: a review of current approaches. J Magn Reson Imaging. 2017;46(5):1263–80.
31. Gao Y, Yang Z, Ren Y, et al. Evaluation myocardial fibrosis in diabetes with cardiac magnetic resonance T1-mapping: correlation with the high-level hemoglobin A1c. Diabetes Res Clin Pract. 2019;150:72–80.
32. Wei J, Nelson MD, Szczepaniak EW, et al. Myocardial steatosis as a possible mechanistic link between diastolic dysfunction and coronary microvascular dysfunction in women. Am J Physiol Hear Circ Physiol. 2016;310(1):H14–9.
33. Rijzewijk LJ, van der Meer RW, Smit JWA, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52(22):1793–9.
34. Dobson R, Burgess MJ, Sprung VS, et al. Metabolically healthy and unhealthy obesity: differential effects on myocardial function according to metabolic syndrome, rather than obesity. Int J Obes. 2016;40(1):153–61.
35. van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res. 2011;92(1):10–8.
36. Pappachan JM, Varughese GI, Sriman R, Arunagirinathan G. Diabetic cardiomyopathy: pathophysiology, diagnostic evaluation and management. World J Diabetes. 2017;8(5):177.
37. Levelt E, Mahmood M, Piechnik SK, et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes. 2016;65(1):44–52.
38. Mahmood M, Pal N, Rayner J, et al. The interplay between metabolic alterations, diastolic strain rate and exercise capacity in mild heart failure with preserved ejection fraction: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2018;20(1):88.
39. Levelt E, GuSSIN G, Neubauer S, McCann GP. Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. Eur J Endocrinol. 2018;178(4):R127–39.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.